Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

United States Gastric and Gastroesophageal Junction Adenocarcinoma Drug Forecast and Market Analysis 2015-2024 - Research and Markets

Research and Markets
Posted on: 20 Oct 16

Research and Markets has announced the addition of the "Gastric and Gastroesophageal Junction Adenocarcinoma - US Drug Forecast and Market Analysis to 2024" report to their offering.

Gastric and gastroesophageal junction adenocarcinoma (G/GEJAC) represents the majority of gastric cancer cases worldwide. It is the fifth most diagnosed cancer globally, and the third most common cause of cancer death in the world. The major treatments for G/GEJAC are chemotherapy-based, but targeted therapies such as HER2 and angiogenesis inhibitors have been approved and are being added to chemotherapy regimens since 2010 and 2014, respectively.

The US is a large G/GEJAC market due to high treatment rates of advanced diseases and higher drug prices than in the rest of the 8MM. Increased sales of G/GEJAC therapies over the forecast period will be driven by increasing disease incident cases, the rapid uptake of newly approved Cyramza, and the approval and increasing uptake of expensive pipeline agents, such as anti-PD-1 immunotherapies and a HER2-targeted therapy.

Key Topics Covered:

1Tables & Figures

2 Introduction

3 Disease Overview

4 Disease Management

5 Competitive Assessment

5.1 Overview

5.2 HER2-Targeted Therapy

5.2.1 Herceptin (trastuzumab)

5.3 Angiogenesis Inhibitors

5.3.1 Cyramza (ramucirumab)

5.3.2 Aitan (apatinib)

5.4 Chemotherapies

5.4.1 TS-1 (tegafur, gimeracil, oteracil)

5.4.2 Abraxane (nab-paclitaxel)

6 Unmet Need and Opportunity

6.1 Overview

6.2 First-Line Therapy for HER2-Negative Patients

6.3 New Molecular Targets for Targeted Therapies

6.4 Effective Perioperative and Postoperative Therapies

6.5 More Efficacious HER2-Targeted Therapies

6.6 Peritoneal Metastases

6.7 Better Clinical Trial Design

6.8 Early Detection of Gastric and Gastroesophageal Adenocarcinomas

7 Pipeline Assessment

7.1 Overview

7.2 Promising Drugs in Phase III Clinical Development

7.3 HER2-Targeted Therapies

7.3.1 Kadcyla (T-DM1; trastuzumab emtansine)

7.3.2 Perjeta (pertuzumab)

7.4 Immune Checkpoint Inhibitors

7.4.1 Keytruda (pembrolizumab)

7.4.2 Opdivo (nivolumab)

7.5 Further Strategies for G/GEJAC Treatment

7.5.1 Napabucasin

7.5.2 Lynparza (olaparib)

7.5.3 Nimotuzumab

7.5.4 TAS-118

7.6 Early/Near-Phase III Pipeline Drugs

7.6.1 GS-5745

7.6.2 Masitinib

7.7 Promising Drugs in Early-Stage Development

7.7.1 Immune Checkpoint Inhibitors

7.7.2 MET-Targeting Drugs

7.7.3 Antibody-Drug Conjugates

7.8 Biosimilars

8 Market Outlook

9 Appendix

For more information about this report visit http://www.researchandmarkets.com/research/x3vbnn/gastric_and

View source version on businesswire.com: http://www.businesswire.com/news/home/20161020006331/en/

Business Wire
www.businesswire.com

Last updated on: 20/10/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.